60 Degrees Pharmaceuticals, Inc. (SXTP) Revenue History
Annual and quarterly revenue from 2020 to present
SXTP Revenue Over Time (2020–2025)
SXTP Revenue Growth History
3 of 5 years with positive growth- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- -46.8%
- FY2022 revenue growth
- -80.8%
- FY2023 revenue growth
- +13.6%
- FY2024 revenue growth
- +139.6%
- FY2025 revenue growth
- +65.5%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $162K | -0.9% |
| Q4 2025 | $303K | +16.0% |
| Q3 2025 | $438K | +223.4% |
| Q2 2025 | $101K | -19.2% |
| Q1 2025 | $164K | +54.8% |
| Q4 2024 | $261K | +512.2% |
| Q3 2024 | $135K | +164.3% |
| Q2 2024 | $125K | +109.9% |
Multi-year avg. share of annual revenue by fiscal quarter
SXTP Revenue Analysis (2020–2025)
Current Revenue & Growth
As of June 28, 2026, 60 Degrees Pharmaceuticals, Inc. (SXTP) generated trailing twelve-month (TTM) revenue of $1.0 million, reflecting slight decline in growth of -0.9% year-over-year. The most recent quarter (Q1 2026) recorded $162,092 in revenue, down 46.6% sequentially.
Historical Growth Trajectory
SXTP's 5-year compound annual growth rate (CAGR) stands at -14.3%, indicating revenue contraction over this period. The 3-year CAGR of +65.2% exceeds the 5-year average, indicating an acceleration in the most recent period. 60 Degrees Pharmaceuticals, Inc.'s highest annual revenue of $2.2 million was recorded in 2020.
Peer Comparison
Compared to Healthcare sector peers — including AEYE (+11.6% YoY), GERN (+68.6% YoY), and NUVB (+1205.5% YoY) — SXTP has underperformed the peer group in revenue growth. Compare SXTP vs AEYE →
SXTP Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SXTPCurrent | $1M | -0.9% | -14.3% | -771.6% | |
 AEYE | $40M | +11.6% | +14.5% | -7.9% | |
 GERN | $184M | +68.6% | +273.5% | -29.3% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 HALO | $1.4B | +39.1% | +39.2% | 58.4% |
SXTP Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.0M | +65.5% | $224K | 22.3% | $-7,758,579 | -771.6% |
| 2024 | $608K | +139.6% | $223K | 36.7% | $-9,714,931 | -1599.0% |
| 2023 | $254K | +13.6% | $-220,977 | -87.1% | $-5,154,583 | -2032.8% |
| 2022 | $223K | -80.8% | $-209,162 | -93.7% | $-1,750,445 | -784.2% |
| 2021 | $1.2M | -46.8% | $310K | 26.7% | $-1,124,102 | -96.9% |
| 2020 | $2.2M | - | $1.5M | 67.8% | $-418,130 | -19.2% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SXTP — Frequently Asked Questions
Quick answers to the most common questions about buying SXTP stock.
Is SXTP's revenue growth accelerating or slowing?
SXTP revenue growth is slowing. TTM revenue is $1M, up -0.9% year-over-year — below the 5-year CAGR of -14.3%. The deceleration suggests maturing end-markets or increased competition.
What is SXTP's revenue history from 2020 to 2026?
60 Degrees Pharmaceuticals, Inc. (SXTP) revenue history spans 2020 to 2026. TTM revenue as of 2026 is $1M, growing at -0.9% YoY. The 5-year CAGR is -14.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SXTP's long-term revenue growth rate (CAGR)?
60 Degrees Pharmaceuticals, Inc.'s 5-year revenue CAGR of -14.3% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -0.9% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SXTP.
Why does SXTP's quarterly revenue fluctuate?
SXTP quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. 60 Degrees Pharmaceuticals, Inc.'s revenue data from 2020 to 2026 shows full historical quarterly detail on this page.
How is SXTP's revenue distributed by segment?
SXTP reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SXTP's revenue compare to industry peers?
60 Degrees Pharmaceuticals, Inc. (SXTP) with TTM revenue of $1M and -0.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.